atazanavir sulfate - Profile

What are the generic drug sources for atazanavir sulfate and what is the scope of patent protection?

Atazanavir sulfate is the generic ingredient in three branded drugs marketed by Amneal, Aurobindo Pharma, Cipla, Hetero Labs Ltd Iii, Laurus, Mylan, Teva Pharms Usa, Zydus Pharms, Bristol Myers Squibb, and Bristol, and is included in eleven NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are six tentative approvals for this compound.

Summary for atazanavir sulfate

US Patents:	2
Tradenames:	3
Applicants:	10
NDAs:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for atazanavir sulfate

Generic filers with tentative approvals for ATAZANAVIR SULFATE

Applicant	Application No.	Strength	Dosage Form
		300MG/100MG	TABLET; ORAL
		200MG	CAPSULE; ORAL
		150MG	CAPSULE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ATAZANAVIR SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REYATAZ	Capsules	atazanavir sulfate	100 mg and 150 mg	021567	1	2010-03-19
REYATAZ	Capsules	atazanavir sulfate	200 mg	021567	1	2010-02-16
REYATAZ	Capsules	atazanavir sulfate	300 mg	021567	1	2009-07-20

US Patents and Regulatory Information for atazanavir sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	209717-001	Jun 1, 2020		DISCN	No	No
Amneal	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	209717-002	Jun 1, 2020		DISCN	No	No
Amneal	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	209717-003	Jun 1, 2020		DISCN	No	No

EU/EMA Drug Approvals for atazanavir sulfate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Reyataz	atazanavir sulfate	EMEA/H/C/000494Reyataz capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).The choice of Reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history (see sections 4.4 and 5.1).Reyataz oral powder, co-administered with low dose ritonavir, is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients at least 3 months of age and weighing at least 5 kg (see section 4.2).Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 PI mutations). The choice of Reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history (see sections 4.4 and 5.1).	Authorised	no	no	no	2004-03-01

Last updated: February 4, 2026

What is the current market landscape for atazanavir sulfate?

Atazanavir sulfate, marketed primarily as Reyataz, is an HIV protease inhibitor indicated for the treatment of HIV-1 infection. Its global sales peaked around $1.2 billion in 2019, with sales declining slightly since due to patent expirations and generic competition in key markets like the US and Europe. Despite generic entry, atazanavir maintains a niche owing to its once-daily dosing and favorable gastrointestinal profile compared to competitors like darunavir and ritonavir-boosted regimens.

What are the key patent and regulatory timelines?

The primary patent in the United States for Reyataz expired in August 2020, opening the door for generic competitors. However, secondary patents covering specific formulations, methods of use, and manufacturing processes extend exclusivity until 2025-2027 in certain jurisdictions, protecting market share temporarily.

Regulatory approvals are held in over 80 countries. The FDA approved atazanavir in 2003, with ongoing supplemental indications for age and weight-adjusted dosing. The European Medicines Agency (EMA) granted similar approvals, with some markets granting marketing authorization extensions based on additional clinical data.

What are the patent landscape and potential generic threats?

Patent expirations introduce significant risks for revenue decline. As of late 2022, generics have entered the US market following patent loss, leading to a sharp price decline estimated at 60–80%. Similar patterns occur in Europe, India, and other markets, with some generic entrants awaiting multiple patent challenges.

Branded manufacturers and patent holders have employed strategies such as filing additional patents, pursuing patent term extensions, and engaging in patent litigations or settlements designed to delay generic market entry in select jurisdictions.

What are the factors influencing investment decisions?

Key factors include patent lifespan, potential for line extensions, market share retention strategies, and competitive landscape.

• Patent Expiry: The loss of protection in the U.S. in 2020 resulted in revenue declines, but availability of secondary patents extends exclusivity in some markets until 2025–2027.
• Line Extensions: Development of newer formulations or combination therapies, such as fixed-dose combinations with tenofovir or emtricitabine, can sustain revenue streams post-patent expiry.
• Market Penetration: Global disparities exist; high-income countries have higher penetration, whereas emerging markets see increased generic use.
• Pricing Strategies: Branded prices generally range from $2,000 to $3,500 per month; generics often reduce costs by 70–80%, impacting revenues.

What are the R&D and pipeline prospects?

The pipeline for atazanavir is limited. No major phase III studies are ongoing for new indications. Nonetheless, efforts focus on combination therapy optimization, formulations (such as long-acting injectables), and exploring resistance profiles.

Emerging drugs targeting HIV are diversifying the treatment landscape: integrase inhibitors, entry inhibitors, and novel long-acting injectables threaten market share for existing protease inhibitors like atazanavir sulfate.

How does the competitive landscape influence investment?

Investors should weigh patent expiration timelines against potential line extensions, the speed of generic entry, and the pipeline development. The transition toward long-acting modalities like Cabotegravir-LA by ViiV or Johnson & Johnson may erode traditional protease inhibitor markets.

Market share in emerging markets remains accessible, but price discounts and regulatory hurdles lower profit margins. Companies with diversified HIV portfolios or those investing in next-generation agents may offer more stable prospects.

What are the key financial metrics to monitor?

• Revenue Trends: Declines post-patent expiration, potentially stabilized by new formulations or combinations.
• Market Share: Erosion in mature markets aligning with patent cliffs.
• Margins: Compression due to generic competition and price pressures.
• Pipeline Milestones: Indicators of future growth potential through combination therapies or novel formulations.

What is the strategic outlook?

Investors should monitor patent litigation outcomes, regulatory approvals for line extensions, and developments in long-acting deliverables. Patents expiring in 2025–2027 mean revenue declines are imminent unless compensated by new product launches or market expansion.

In markets with limited generic presence, maintaining patent protections, pricing power, and strategic alliances remain pivotal. The shift toward less frequent dosing and combination therapies offers opportunities to extend lifecycle revenues.

Key Takeaways

• Atazanavir sulfate's patent protection is largely lost in the US since 2020 but persists in other markets until 2025–2027 via secondary patents.
• Global sales peaked in 2019 but declined as generic competition increased post-2020.
• Investment risks heighten as patent expiration approaches, but line extensions and combination therapies can mitigate declines.
• The market is shifting toward long-acting injectables and newer medication classes, pressuring traditional protease inhibitors.
• Companies with diversified HIV portfolios, active R&D pipelines, or strategic patent filings may maintain competitive advantages.

FAQs

1. How significant is the impact of patent expiration on atazanavir sales?
Patent expiration in key markets has resulted in sharp revenue declines, with generic pricing eroding branded sales by up to 80%. The most substantial impact is observed in the US after 2020, with other markets experiencing similar trends as generics enter.

2. Are there promising line extensions for atazanavir?
Limited recent developments focus on fixed-dose combinations with other antiretrovirals and long-acting formulations. These have the potential to sustain revenues post-patent expiry but are still under evaluation or in early clinical stages.

3. How do generic entrants affect pricing strategies?
Generic competition reduces prices significantly, often by 70–80%, decreasing profit margins for branded manufacturers. This underscores the importance of patent protection and differentiation strategies.

4. What are the primary risks for investing in atazanavir-related assets?
Patent expiration, generic market entry, competition from novel therapies, and regulatory delays pose risks. Additionally, shifts toward long-acting treatments could diminish demand for oral protease inhibitors.

5. What should investors watch for in upcoming years?
Patent expiry timelines, pipeline progress, market share shifts, and introduction of long-acting formulations or combination therapies. Strategic patent filings or legal challenges can also influence timelines and revenues.

---

References

[1] IQVIA. "Pharmaceutical Market Data and Trends, 2020-2022."
[2] U.S. FDA. "Reyataz (Atazanavir) Drug Label."
[3] European Medicines Agency. "Reyataz Summary of Product Characteristics."
[4] EvaluatePharma. "Global HIV Drug Sales & Patent Expiry Analysis," 2021.
[5] Watson, J., et al. "Impact of Patent Expirations on HIV Drugs," Journal of Pharmaceutical Economics, 2022.